Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients

Arthritis & Rheumatism, 04/06/2012

This study reports for the first time that the inhibition of interleukin–6 (IL–6) function by Tocilizumab (TCZ) restores the Th17/Treg imbalance in Rheumatoid Arthritis (RA) patients.

Print Article Summary